Non-small cell lung cancer
Conditions
Interventions
experimental group:Ginseng Polysaccharides and immunotherapy
Sponsors
Kiang Wu Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged from 18 to 80 years; 2. Histologically confirmed non-small cell lung cancer, metastatic or unresectable lung cancer, with measurable lesions; 3 Will receive immunotherapy as frontline therapy. 4. ECOG performance status 0 or 3 before treatment; 5 Anticipated life expectancy >= 3 month; 6. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. Written informed consent signed.
Exclusion criteria
Exclusion criteria: 1. Diagnosed as any second primary malignant tumor in 5 years before inclusion. 2. Known infection of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or congenital immune deficiency diseases, organ transplantation history 3. Other severe acute or chronic physiological or psychiatric condition. 4. Existence of any disease affecting drug absorption, distribution and elimation. 5. Administration of any other anti-tumor therapy (including but not limited to radiotherapy, chemotherapy, traditional Chinese medicine, surgery, molecular targeted therapy, immunotherapy or biological therapy) 4 weeks before inclusion. 6. Long-term steroid therapy required. 7. Allergies or previous history of severe allergies to Ginseng or immunotherapy. 8. Presence of third space fluid that cannot be controlled by drainage or other means (i.e. pleural effusion or ascites); 9. Following conditions occur in the 6 months before drug administration: severe/ unstable angina pectoris, myocardial infarction, congestive heart failure with symptoms, cerebrovascular accident, including transient ischemic attack, pulmonary embolism, >= grade II renal dysfunction, and other severe diseases that investigators judged to be unsuitable for this trial; 10. Unable to receive immunotherapy or Ginseng as required, or unable to follow up in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease Control Rate;Overall Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression Free Survival; | — |
Countries
China
Contacts
Public ContactCao Yabing
Department of Oncology, Kiang Wu Hospital
Outcome results
None listed